AG10 for Cardiomyopathy

Recruiting in Palo Alto (17 mi)

+8 other locations

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Eidos Therapeutics, a BridgeBio company

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of AG10 administered on a background of stable heart failure therapy.

Eligibility Criteria

This trial is for patients with cardiomyopathy who have completed a prior AG10 study. Participants must be stable enough to follow the treatment plan and agree to use contraception if necessary. Those at risk of heart transplant, on certain other treatments, or with significant health risks are excluded.

Exclusion Criteria

I am not pregnant or breastfeeding, or I agree to stop breastfeeding to participate.

Participant Groups

The study tests the long-term safety and effects of AG10 in individuals with cardiomyopathy while they continue their usual heart failure therapy. It's an open-label trial, meaning both researchers and participants know what treatment is being given.

1Treatment groups

Experimental Treatment

Group I: Open-LabelExperimental Treatment1 Intervention